Natera, Inc. (ntra)
NTRA — Company Overview
Natera, Inc. (NTRA) trades on NMS as part of the Healthcare peer group (Diagnostics & Research).
| Ticker | NTRA |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Exchange | NMS |
| Market cap | $56.33B |
| Last price | $390.79 |
| Size category | Large Cap |
NTRA — Business Description
NTRA represents a Diagnostics & Research business in the Healthcare segment. Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which scr…
Official website: https://www.natera.com.
NTRA — Investment Thesis
At a high level, NTRA offers exposure to Healthcare with metrics outlined below from public market data.
- Revenue is expanding at roughly 37.7% year-over-year (public data).
- Equity market capitalization is approximately $56.33B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
NTRA — Financial Health
Key financial health indicators for Natera, Inc. are derived exclusively from public data — no proprietary estimates.
Negative profit margin (-7.1%) signals near-term profitability pressure. Positive free cash flow of $104.03M supports balance-sheet flexibility.
| Forward P/E | -3751.82× |
| Price / Sales | 20.81× |
| Price / Book | 30.81× |
| Gross margin | 65.2% |
| Operating margin | -10.3% |
| Profit margin | -7.1% |
| Return on equity | -12.5% |
| Debt / Equity | 13.09 |
| Free cash flow | $104.03M |
NTRA — Growth Outlook
Growth outlook for Natera, Inc. (NTRA) depends on demand trends in Diagnostics & Research and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 37.7% indicates strong top-line momentum.
- Price is 1.0% below the 52-week high.
NTRA — Competitive Position
Natera, Inc. (NTRA) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Diagnostics & Research.
- Market capitalization of $56.33B places NTRA among large-cap peers.
- Gross margin near 65.2% may reflect pricing power or favorable mix.
NTRA — Strengths
Strengths for Natera, Inc. (NTRA) inferred from public financial metrics:
- Revenue growth of 37.7% year-over-year.
- Gross margin of 65.2% supports competitive unit economics.
- Positive free cash flow ($104.03M).
- Moderate leverage (debt/equity 13.09).
- Large Cap scale ($56.33B) may provide distribution and funding advantages.
- Price near 52-week highs — positive price momentum on public markets.
NTRA — Weaknesses
Weaknesses and pressure points for Natera, Inc. (NTRA) based on available data:
- Thin profit margin (-7.1%).
- High beta (1.53) amplifies market swings.
NTRA — Opportunities
- Sustained revenue growth (37.7%) could support multiple expansion if margins hold.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
NTRA — Risks
- Beta of 1.53 implies above-market volatility.
- Thin margins leave less room for operational missteps.
NTRA — Summary
Natera, Inc. (NTRA) is a large-cap Healthcare company focused on Diagnostics & Research, listed on NMS. Last price $390.79 with market cap $56.33B. Revenue grew 37.7% year-over-year per public data. Notable strengths include revenue growth of 37.7% year-over-year. Key watch items include thin profit margin (-7.1%). Premium Terminal tools for Natera, Inc. add ownership analytics, news, and richer estimate history beyond this public summary.
Start Free — open NTRA in Vest Terminal
Access live data, filings, ownership, and analysis for Natera, Inc..
Natera, Inc. FAQ
What does Natera, Inc. (NTRA) do?
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients p…
What is NTRA's P/E ratio?
Natera, Inc. has a trailing P/E of N/A× based on publicly available market data.
Does NTRA pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is NTRA in?
Natera, Inc. is classified in Healthcare (Diagnostics & Research) on NMS.
What is NTRA's market capitalization?
Approximate market cap: $56.33B.
What are the main risks for NTRA?
Key risks include above-average volatility (beta 1.53), among factors on this page.
What are the strengths of NTRA?
Potential positives include revenue growth of 37.7% year-over-year, gross margin of 65.2% supports competitive unit economics.
Where can I get analyst estimates for NTRA?
Public analyst price targets and consensus for Natera, Inc. are on the free /stocks/ntra/estimates page. Deeper estimate history and models are available in Vest Terminal.